☰

Emil Bulatov - Publications

Affiliations: 
2010-2014 School of Life Sciences University of Dundee, Dundee, Scotland, United Kingdom 
Tree Info Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Khadiullina R, Mirgayazova R, Davletshin D, Khusainova E, Chasov V, Bulatov E. Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry. Life (Basel, Switzerland). 13. PMID 36675980 DOI: 10.3390/life13010031  0.315
2022 Korenev G, Yakukhnov S, Druk A, Golovina A, Chasov V, Mirgayazova R, Ivanov R, Bulatov E. USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective. Cancers. 14. PMID 36428632 DOI: 10.3390/cancers14225539  0.315
2022 Stephenson Clarke JR, Douglas LR, Duriez PJ, Balourdas DI, Joerger AC, Khadiullina R, Bulatov E, Baud MGJ. Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C. Acs Pharmacology & Translational Science. 5: 1169-1180. PMID 36407959 DOI: 10.1021/acsptsci.2c00164  0.645
2021 Chasov V, Zaripov M, Mirgayazova R, Khadiullina R, Zmievskaya E, Ganeeva I, Valiullina A, Rizvanov A, Bulatov E. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. Frontiers in Immunology. 12: 707734. PMID 34484205 DOI: 10.3389/fimmu.2021.707734  0.375
2021 Chasov V, Zaripov M, Mirgayazova R, Khadiullina R, Zmievskaya E, Ganeeva I, Valiullina A, Rizvanov A, Bulatov E. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies Frontiers in Immunology. 12. DOI: 10.3389/fimmu.2021.707734  0.375
2020 Zagidullin A, Milyukov V, Rizvanov A, Bulatov E. Novel approaches for the rational design of PROTAC linkers. Exploration of Targeted Anti-Tumor Therapy. 1: 381-390. PMID 36046487 DOI: 10.37349/etat.2020.00023  0.351
2020 Chasov V, Mirgayazova R, Zmievskaya E, Khadiullina R, Valiullina A, Clarke JS, Rizvanov A, Baud MGJ, Bulatov E. Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy Frontiers in Oncology. 10. PMID 32974171 DOI: 10.3389/Fonc.2020.01460  0.633
2020 Zagidullin A, Milyukov V, Rizvanov A, Bulatov E. Novel approaches for the rational design of PROTAC linkers Exploration of Targeted Anti-Tumor Therapy. 1: 381-390. DOI: 10.37349/etat.2020.00023  0.351
2019 Mingaleeva R, Sagdeeva A, Sayarova R, Bulatov E, Miftakhova R, Rizvanov A. Expression of mutant p53 affects cancer cell sensitivity to topotecan Annals of Oncology. 30: v803. DOI: 10.1093/Annonc/Mdz269.021  0.435
2018 Bulatov E, Sayarova R, Mingaleeva R, Miftakhova R, Gomzikova M, Ignatyev Y, Petukhov A, Davidovich P, Rizvanov A, Barlev NA. Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors. Cell Death Discovery. 4: 103. PMID 30455989 DOI: 10.1038/S41420-018-0120-Z  0.417
2018 Bulatov E, Valiullina A, Sayarova R, Rizvanov A. Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases. Immunology Letters. 202: 44-51. PMID 30099009 DOI: 10.1016/J.Imlet.2018.08.001  0.452
2018 Bulatov E, Zagidullin A, Valiullina A, Sayarova R, Rizvanov A. Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets. Frontiers in Pharmacology. 9: 450. PMID 29867461 DOI: 10.3389/Fphar.2018.00450  0.469
2018 Valiullina A, Petukhov A, Sayarova R, Zhuravleva M, Kletukhina S, Malanin S, Bulatov E, Rizvanov A. Screening for Immunosuppressive Genes Responsible for Resistance Towards CAR-T Cell Therapy in Cancer Cells Blood. 132: 4965-4965. DOI: 10.1182/Blood-2018-99-118241  0.311
2017 Valiullina AK, Gomzikova M, Garanina EE, Khaibullin T, Rizvanov A, Bulatov E. Small Molecule p53-MDM2 Inhibitors As Potential Regulators of p53-Dependent Genes Expression in Multiple Sclerosis Blood. 130: 4820-4820. DOI: 10.1182/Blood.V130.Suppl_1.4820.4820  0.382
2016 Bulatov E, Khaiboullina S, dos Reis HJ, Palotás A, Venkataraman K, Vijayalakshmi M, Rizvanov A. Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases Bionanoscience. 6: 341-344. DOI: 10.1007/S12668-016-0233-X  0.388
2015 Gadd MS, Bulatov E, Ciulli A. Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases. Plos One. 10: e0131218. PMID 26121586 DOI: 10.1371/Journal.Pone.0131218  0.569
2015 Bulatov E, Ciulli A. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochemical Journal. 467: 365-386. PMID 25886174 DOI: 10.1042/Bj20141450  0.639
2015 Bulatov E, Martin EM, Chatterjee S, Knebel A, Shimamura S, Konijnenberg A, Johnson C, Zinn N, Grandi P, Sobott F, Ciulli A. Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2). The Journal of Biological Chemistry. 290: 4178-91. PMID 25505247 DOI: 10.1074/Jbc.M114.616664  0.63
Show low-probability matches.